Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 833

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 9B
Chunk 833
---
 February 2024, we issued
and sold an aggregate of 10,039 shares of Series A Preferred Stock, 6,127 Series A Common Warrants and 2,500 Preferred Warrants, at a
price of $800 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds
of up to $2.0 million if the Preferred Warrants are exercised.

The following table summarizes
the shares of our Series A Preferred Stock issued to our related parties:

    Purchasers 
    Shares
                                            of
 Series A Preferred

                                            Stock  
    Total Purchase Price 
  
    Daniel Corey(1) 
     150  
    $150,000 
  
    Atwood-Edminster Trust dtd 4-2-2000 (2) 
     1,002  
    $1,002,000 
  
    Chris Ehrlich(3) 
     275  
    $275,000 

  (1) Daniel Corey served as the Chief Technology Officer and a member of the board of directors of the Company from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024. 

  (2) Brian G. Atwood served as Chairman and Chief Executive Officer of the Company from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination in February 2024. Mr. Atwood is currently a member of the board of directors of the Company and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. 

  (3) Chris Ehrlich has served as the Chairman and Chief Executive Officer of the Company since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer of the Company from October 2024 to November 2024, (ii) Vice Chairman of the board of directors of the Company from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. 

NOTE
15 – SUBSEQUENT EVENTS

On January 6, 2025, 625 Series
A Preferred Warrants were exercised into 625 shares of Series A Preferred Stock for